Latest MediTemp News
Oct 14, 2015
Tags: bio med ( 2 ) , health ( 8 ) , male fertility Generex To Aqurie Controlling Share Israeli Biotech Company October 14, 2015 | Israeli bio-medical company Meditemp has signed a non-binding Letter of Intent with Generex Biotechnology , which according to the letter, could acquire a 51% equity interest in MediTemp in exchange for a purchase price of $5 million. Founded in 2007, MediTemp has developed a proprietary cooling technology designed to improve sperm quality in men rendered infertile due to varicoceles, a condition characterized by enlarged veins (varicose) within the scrotum. The company’s solution is called Varicure, a wearable, compact, portable and comfortable device that facilitates localized cooling of the testicles with the aim of enhancing male fertility by improving sperm quality.
MediTemp Frequently Asked Questions (FAQ)
Where is MediTemp's headquarters?
MediTemp's headquarters is located at P.O.Box 45810, Haifa.
What is MediTemp's latest funding round?
MediTemp's latest funding round is Corporate Majority.
Who are the investors of MediTemp?
Investors of MediTemp include Generex Biotechnology.